Entrada Therapeutics

Karla MacDonald, Entrada’s Chief Corporate Affairs Officer, and Sarah Friedhoff, Head of Patient Advocacy, will be attending Action Duchenne’s 2024 Annual International Conference in Leicestershire, United Kingdom on November 8-9.    The theme for this year’s conference is ‘Educating, Connecting and Wellbeing’. We look forward to joining the Duchenne community to gain insights and, most importantly, turn them into actions. If you are attending the conference, please come say hello!     For more information and to register, click here: https://lnkd.in/dj75aC9M   #Duchenne #DMD #EntradaHere

Today, we announced third quarter 2024 financial results and highlighted recent business updates. The recent data presented at the World Muscle Society enhance our proposed regulatory packages, and we remain on track with our global regulatory filings for both ENTR-601-44 and ENTR-601-45 this quarter. Vertex has also made significant progress, announcing the SAD portion of their Phase 1/2 trial of VX-670 in DM1 is now complete, and they have initiated the MAD portion of the trial. Our team continues to work hard across our entire pipeline in an effort to bring these important potential therapies to patients. For further details, visit: https://lnkd.in/eTCv6YsP   #EntradaHere #DuchenneMuscularDystrophy #FinancialResults

Our Entrada Planning & Impact Committee (EPIC) team does not disappoint! Earlier this week, they conjured a wickedly fun Halloween celebration that included fantastic costumes and a thrilling murder mystery that kept everyone on the edge of their seats. One Entradan earned bonus points for creatively incorporating our values into their costume! Check out some of the highlights.   A big shoutout to the EPIC team for pulling together this event!    #HappyHalloween #Halloween2024 #EntradaHere

We're on a mission to develop intracellular therapeutics to treat serious diseases. If you're passionate about contributing to groundbreaking scientific and therapeutic advances, we want you on our team!   Apply today: https://lnkd.in/eXjmC27B   #Hiring #Biotech #EntradaHere

Yesterday, Dipal Doshi, Entrada’s Chief Executive Officer, spoke at Boston CEO on the ‘Company Formation: Building A Biotech’ panel. A big thanks to Longwood Healthcare Leaders for hosting this event, as well as the other panelists who contributed to an engaging conversation.    #EntradaHere #Biotech #BostonCEO

We are delighted to watch our team grow. Please join us in welcoming our newest Entradans: · Gregory Jones, Ph.D. (Associate Director, Drug Product Development & Manufacturing) · Jasmine Feng (Senior Research Associate, Ocular Research) · David Weinstein, MD, PhD (Vice President, Clinical Development) We would also like to congratulate Owen W. Erickson (Specialist, Patient Advocacy & Corporate Affairs) who recently transitioned from a contractor role to full-time Entradan. We are thrilled to have you on our team! Interested in joining our team of dedicated Entradans? Explore our careers page and apply: https://lnkd.in/eXjmC27B #TopPlaceToWork #EntradaHere #Hiring

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Last week, the Entrada team traveled to Prague for the 29th Annual Congress of the World Muscle Society. Natarajan Sethuraman, PhD, President of Research and Development, and Sweta Girgenrath, PhD, Vice President, Neuromuscular, presented clinical and preclinical data in support of our expanding Duchenne franchise.    If you missed the presentations, they are available here: https://lnkd.in/ed8345DB   #WMS2024 #Duchenne #DMD

As part of our Hispanic Heritage Month celebration, Entrada hosted a panel discussion to spotlight the diversity in our Hispanic and Latinx community! The conversation explored how their backgrounds influenced their life choices while also sharing ideas about inclusion and belonging at work. Each panelist ended with a favorite memory from their culture.    Please join us in giving a round of applause to our panelists: Jia Qi Cheng Zhang, PhD, Scientist I Arianna Bonilla, Senior Research Associate Paulina Baca, Senior Research Associate Weimer Macuri-Espinoza, Research Associate I   A big thank you to our amazing moderator Sara Blake, Senior Research Associate, for facilitating the discussion! We’d also like to thank Nelsa Estrella, Ph.D., Director of Neuromuscular Therapeutics, for her leadership and pulling together such a special event!     #EntradaHere #HispanicHeritageMonth #MesdelaHerenciaHispana

On this Indigenous Peoples' Day, Entrada Therapeutics pays tribute to the resilience, wisdom and rich cultural heritage of Indigenous communities worldwide. Let us celebrate by honoring the knowledge, traditions and contributions of Indigenous communities, and by working together towards a healthier and more equitable future.    #IndigenousPeoplesDay #Biotech #EntradaHere